Primary Site >> Colorectal Cancer
Gene >> PROK1
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|
|
Ref: Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. PMID: 9918206 Ref: Comparative analysis of the effects of flavonoids on proliferation, cytotoxicity, and apoptosis in human colon cancer cell lines. PMID: 10443335 |
Ref: Technology evaluation: PK1, Pfizer/Cancer Research UK. PMID: 12870445 |
Ref: Angiogenesis and tumor proliferation/metastasis of human colorectal cancer cell line SW620 transfected with endocrine glands-derived-vascular endothelial growth factor, as a new angiogenic factor. PMID: 15026321 |
Ref: Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) expression in colorectal cancer. PMID: 17786959 |
Ref: Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. PMID: 19424581 |
Ref: Endocrine gland-derived vascular endothelial growth factor strengthens cell invasion ability via prokineticin receptor 2 in colon cancer cell lines. PMID: 23135359 Ref: Prokineticin 1 expression in gastrointestinal tumors. PMID: 24324064 |
Ref: Anti-prokineticin1 (PROK1) monoclonal antibody suppresses angiogenesis and tumor growth in colorectal cancer. PMID: 24838366 |
Ref: Prokineticin 1 protein expression is a useful new prognostic factor for human sporadic colorectal cancer. PMID: 25331005 Ref: The anti-tumor effect is enhanced by simultaneously targeting VEGF and PROK1 in colorectal cancer. PMID: 25788276 Ref: The prognosis was poorer in colorectal cancers that expressed both VEGF and PROK1 (No correlation coefficient between VEGF and PROK1). PMID: 26318037 |
Ref: Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) and its receptor PROKR2 are associated to human colorectal cancer progression and peritoneal carcinomatosis. PMID: 29226856 |